Abstract
Aim. The goal of the study is to demonstrate the binding sites for curcumin on the protein carriers - bovine serum albumin and diphtheria toxoid CRM197. BSA was chosen as a potential non-specific protein carrier because of its widely used in medicine as a drug carrier. Methods. In the investigation, both spectrophotometric and molecular docking methods were used. Results. Two stable binding sites were demonstrated for BSA to bind curcumin. CRM197 was taken as a well-studied carrier protein with its own antitumor activity and has been investigated as a specific carrier with a high affinity for cancer cells with overexpression of epidermal growth factor receptor. Our results showed one possible curcumin binding site, making CRM197 an ideal specific curcumin delivery platform that provides at least an additive effect in anticancer therapies. Conclusions. In conclusion, both studied proteins form stable complexes with curcumin that can lay in base of the commercial drug application.
Publisher
National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications)
Subject
General Earth and Planetary Sciences,General Environmental Science
Reference20 articles.
1. Li J, Wang R, Gao J. Novel anticancer drugs approved in 2020. Drug Discov Ther. 2021;15(1):44¾ https://doi.org/10.5582/ddt.2021.01013. PMID: 33692282
2. Kumar A, Singh AK, Singh H, Vijayan V, Kumar D, Naik J, Thareja S,Yadav JP, Pathak P, Grishina M, Verma A, Khalilullah H, Jaremko M, Emwas AH, Kumar P. Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective. Pharmaceuticals (Basel). 2023 Feb 14;16(2):299. https://doi.org/3390/ph16020299. PMID: 37259442; PMCID: PMC9965678.
3. Dagar G, Gupta A, Masoodi T, Nisar S, Merhi M, Hashem S, Chauhan R, Dagar M, Mirza S, Bagga P, Kumar R, Akil ASA, Macha MA, Haris M, Uddin S, Singh M, Bhat AA. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. J.Transl Med. 2023 Jul 7;21(1):449. https://doi.org/1186/s12967-023-04292-3. Erratum in: J.Transl Med. 2023 Aug 25;21(1):571. PMID: 37420216; PMCID: PMC10327392.
4. Trinidad-Calderón PA, Varela-Chinchilla CD, García-Lara S. Natural Peptides Inducing Cancer Cell Death: Mechanisms and Properties of Specific Candidates for Cancer Therapeutics. Molecules. 2021 Dec 9;26(24):7453. https://doi.org/3390/molecules26247453. PMID: 34946535; PMCID: PMC8708364.
5. Kalanaky S, Hafizi M, Fakharzadeh S, Vasei M, Langroudi L, Janzamin E, Hashemi SM, Khayamzadeh M, Soleimani M, Akbari ME, Nazaran MH. BCc1, thenovel antineoplastic nanocomplex, showed potent anticancer effects in vitro and invivo. Drug Des Devel Ther. 2015 Dec 30;10:59¾ https://doi.org/10.2147/DDDT.S89694.PMID: 26766901; PMCID: PMC4699513.